Adults with sickle cell anemia (SCA) and healthy controls with greater economic deprivation have older brain age, acco ...

DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...

"In one of the largest trials on iron deficiency, conducted with nearly 600 pregnant women at antenatal clinics in Malawi, ...

Mira-Bhayandar: A 26-year-old woman with extremely low hemoglobin levels and battling catastrophic antiphospholipid antibody syndrome (APLA) syndrome during her eighth month of pregnancy, delivered a ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

New data from a Phase 1b clinical trial testing Fulcrum's pociredir for sickle cell disease are expected by the middle and ...

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204 , an investigational ...

DelveInsight’s ‘Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an ...